×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GLMD – galmed pharmaceuticals ltd. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GLMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/14
07:30 am
glmd
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
High
Report
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
4/9
10:38 am
glmd
Galmed Pharmaceuticals Ltd. Unlocks CNS Potential with New Brain-Penetrating Aramchol Formulation [TheStreet.com]
Low
Report
Galmed Pharmaceuticals Ltd. Unlocks CNS Potential with New Brain-Penetrating Aramchol Formulation [TheStreet.com]
4/9
07:30 am
glmd
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
High
Report
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
3/31
04:30 pm
glmd
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 [TheStreet.com]
Medium
Report
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 [TheStreet.com]
3/31
04:15 pm
glmd
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Medium
Report
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
1/30
04:15 pm
glmd
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Medium
Report
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/14
07:42 am
glmd
Form 6-K Galmed Pharmaceuticals For: Apr 14
Medium
Report
Form 6-K Galmed Pharmaceuticals For: Apr 14
4/9
08:40 am
glmd
Form 6-K Galmed Pharmaceuticals For: Apr 09
High
Report
Form 6-K Galmed Pharmaceuticals For: Apr 09
4/2
06:07 am
glmd
Form EFFECT Galmed Pharmaceuticals
Low
Report
Form EFFECT Galmed Pharmaceuticals
3/31
04:36 pm
glmd
Form POS AM Galmed Pharmaceuticals
High
Report
Form POS AM Galmed Pharmaceuticals
3/31
04:16 pm
glmd
Form 20-F Galmed Pharmaceuticals For: Dec 31
Medium
Report
Form 20-F Galmed Pharmaceuticals For: Dec 31
3/18
07:46 am
glmd
Form 3 Galmed Pharmaceuticals For: Mar 18 Filed by: Nissimov Brueck Liat
Low
Report
Form 3 Galmed Pharmaceuticals For: Mar 18 Filed by: Nissimov Brueck Liat
3/18
07:46 am
glmd
Form 3 Galmed Pharmaceuticals For: Mar 18 Filed by: SIDRANSKY DAVID
Low
Report
Form 3 Galmed Pharmaceuticals For: Mar 18 Filed by: SIDRANSKY DAVID
3/18
07:46 am
glmd
Form 3 Galmed Pharmaceuticals For: Mar 18 Filed by: Poshinski Amir
Low
Report
Form 3 Galmed Pharmaceuticals For: Mar 18 Filed by: Poshinski Amir
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/2
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Canaccord Genuity. They set a "buy" rating on the stock.
29.3%
3/18 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 18.0%
3/13 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its price target lowered by analysts at B. Riley from $28.00 to $11.00. They now have a "buy" rating on the stock. 13.2%
10/31 Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019 13.1%
1/7 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. 11.9%
2/4 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $18.00 price target on the stock. 11.9%
1/4 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.3%
11/10 Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT [Yahoo! Finance News] 5.7%
8/5 Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.4%
8/6 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $20.00 price target on the stock. 3.9%
3/18 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 18.0%
3/13 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its price target lowered by analysts at B. Riley from $28.00 to $11.00. They now have a "buy" rating on the stock. 13.2%
10/31 Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019 13.1%
1/7 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. 11.9%
2/4 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $18.00 price target on the stock. 11.9%
1/4 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.3%
11/10 Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT [Yahoo! Finance News] 5.7%
8/5 Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.4%
8/6 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $20.00 price target on the stock. 3.9%
TOP News Decliners
3/12
Q4/2019 12/31/2019 EPS -0.390 ZacksConsensus -0.370 ActVsEst (0.020) - Miss
-19.5%
8/5 Form 6-K Galmed Pharmaceuticals For: Jun 30 -17.8%
7/22 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Laidlaw. They set a "buy" rating on the stock. -11.7%
2/6 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.50 price target on the stock. -11.1%
1/30 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock, down previously from $59.00. -11.1%
11/6 Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results -11.0%
10/23 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price target on the stock. -8.0%
5/7 Q1/2019 3/31/2019 EPS -0.170 ZacksConsensus -0.190 ActVsEst 0.020 - Beat -7.7%
3/5 Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12 -6.2%
3/17 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. -5.1%
8/5 Form 6-K Galmed Pharmaceuticals For: Jun 30 -17.8%
7/22 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Laidlaw. They set a "buy" rating on the stock. -11.7%
2/6 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.50 price target on the stock. -11.1%
1/30 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock, down previously from $59.00. -11.1%
11/6 Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results -11.0%
10/23 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price target on the stock. -8.0%
5/7 Q1/2019 3/31/2019 EPS -0.170 ZacksConsensus -0.190 ActVsEst 0.020 - Beat -7.7%
3/5 Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12 -6.2%
3/17 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: